Back to top
more

Amphastar Pharmaceuticals (AMPH)

(Delayed Data from NSDQ)

$42.44 USD

42.44
464,992

+1.14 (2.76%)

Updated May 15, 2024 04:00 PM ET

After-Market: $42.47 +0.03 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (52 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why

by Zacks Equity Research

Amphastar Pharma (AMPH) shares are up 89.1% year to date due to the acquisition of Baqsimi from Lilly. The company also receives FDA approval for Naloxone.

Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why

by Zacks Equity Research

Sales of Lilly's (LLY) new drug, Mounjaro are already benefiting from strong demand trends. Lilly expects regulatory decisions for some key pipeline candidates this year, which are key to growth.

HCA Healthcare (HCA) Rises 24% in a Year: More Room to Run?

by Zacks Equity Research

HCA Healthcare (HCA) is well-poised for growth on the back of improved patient occupancy levels, effective telehealth services suite and solid cash-generating abilities.

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: Celsius, Adobe, Curtiss-Wright in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical

by Zacks Equity Research

Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical are part of the Zacks Industry Outlook article.

Is Amphastar (AMPH) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.

Cigna (CI) Unit Ties Up to Offer Digital Health Tool to Clients

by Zacks Equity Research

Cigna's (CI) division, Cigna Healthcare, teams up with Virgin Pulse to make an effective digital health solution available to its clients, who can now improve their well-being.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

by Sundeep Ganoria

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.

Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Dr. Reddy's Laboratories Ltd (RDY) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Doctor Reddy's (RDY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Amphastar (AMPH) delivered earnings and revenue surprises of 14.04% and 6.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up

by Zacks Equity Research

TEVA's second-quarter results were strong as it beat estimates for earnings as well sales.

BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -13.95% and 65.14%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Dr. Reddy's (RDY) reports better-than-expected fiscal first-quarter 2024 results.

Amphastar Pharmaceuticals (AMPH) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $61.38, moving -0.44% from the previous trading session.

Amphastar Pharmaceuticals (AMPH) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Amphastar (AMPH) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Amphastar's (AMPH) revenues in the second quarter of 2023 are expected to have been driven by the sales of its high-margin pharmaceutical products.

Amphastar Pharmaceuticals (AMPH) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) closed at $63.25 in the latest trading session, marking a +1.48% move from the prior day.

The Zacks Analyst Blog Highlights Abercrombie & Fitch, InterDigital, Shake Shack, Amphastar and PGT Innovations

by Zacks Equity Research

Abercrombie & Fitch, InterDigital, Shake Shack, Amphastar and PGT Innovations are included in this Analyst Blog.

Nalak Das headshot

5 Must-Buy High-Flying Mid-Caps to Enhance Your Portfolio

by Nalak Das

We have narrowed our search to five mid-cap stocks with more than 50% returns year to date. These are: PGTI, SHAK, IDCC, ANF, AMPH.

BridgeBio Pharma (BBIO) Moves 75.9% Higher: Will This Strength Last?

by Zacks Equity Research

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Amphastar Pharmaceuticals (AMPH) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $55.87, moving +1.07% from the previous trading session.

Here's Why Investors Should Add Encompass Health (EHC) to Portfolio

by Zacks Equity Research

Encompass Health (EHC) remains well-poised for growth on the back of solid demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.

Amphastar (AMPH) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Align Technology (ALGN) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.